Krzysztof Kloc
Krzysztof Kloc has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Aleksandra Matjaszek
Assignity, Poland
1 shared publication- Ekkehard Beck
Moderna, Inc., Cambridge, MA 02142, USA
1 shared publication - Elżbieta Łukomska
Clever-Access, 30-415 Krakow, Poland
1 shared publication - Keya Joshi
Moderna, Inc., Cambridge, MA 02142, USA
1 shared publication - Malwina Kowalska
Assignity, Poland
1 shared publication - Nicolas Van de Velde
Moderna, Inc., 325 Binney Street, Cambridge, MA 02142, USA
1 shared publication
Latest Publications
- Open Access
- 2 September 2024
- Published by MDPI AG in Preprints.org
Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID Conditions: Findings from a Literature Review
Approximately 10–20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs associated with LC. Because LC is not clearly defined and often remains undiagnosed, studies reporting on long-term follow-up of individuals with a COVID-19 diagnosis were also included. Among the 41 publications included, 36 reported on HCRU and 16 on costs. Individuals with LC had significantly elevated HCRU and healthcare cost vs controls without a COVID-19 diagnosis over ≥15 months, with a 7.6%–13.1% increase in total healthcare costs per person per month as assessed by difference-in-difference analysis. Among studies that did not specifically refer to LC, having a COVID-19 diagnosis was associated with a significant 4–10% increase in long-term total HCRU over 6–8 months and a 1.3- to 2.9-fold relative increase in total healthcare costs over 6 months. Due to the heterogeneity of included studies, high-quality evidence is needed to better understand the economic burden of LC. In the absence of effective treatments, prioritizing prevention of acute COVID-19, e.g., through vaccination, may be crucial for preventing LC and the associated long-term HCRU and medical spending.
- 2 September 2024
- Published by MDPI AG in Preprints.org
Open AccessHealthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID Conditions: Findings from a Literature Review
Approximately 10–20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs associated with LC. Because LC is not clearly defined and often remains undiagnosed, studies reporting on long-term follow-up of individuals with a COVID-19 diagnosis were also included. Among the 41 publications included, 36 reported on HCRU and 16 on costs. Individuals with LC had significantly elevated HCRU and healthcare cost vs controls without a COVID-19 diagnosis over ≥15 months, with a 7.6%–13.1% increase in total healthcare costs per person per month as assessed by difference-in-difference analysis. Among studies that did not specifically refer to LC, having a COVID-19 diagnosis was associated with a significant 4–10% increase in long-term total HCRU over 6–8 months and a 1.3- to 2.9-fold relative increase in total healthcare costs over 6 months. Due to the heterogeneity of included studies, high-quality evidence is needed to better understand the economic burden of LC. In the absence of effective treatments, prioritizing prevention of acute COVID-19, e.g., through vaccination, may be crucial for preventing LC and the associated long-term HCRU and medical spending.